Kadmon enters agreement with Chiromics for chemical compounds library
US-based pharmaceutical company, Kadmon and Chiromics have inked a deal under which Kadmon has secured a non-exclusive license for use of Chiromics' chemical compound libraries that enable discovery and development of pharmaceutical products.
The technology used to build Chiromics' libraries, employs a chemical synthesis technique referred to as 'cascade catalysis.'
According to the company, cascade catalysis helps create a diverse collection of molecules that are complex and differentiated from, existing pharmaceutical libraries.
The financial terms of the deal have not been disclosed.
Kadmon chairman and CEO Samuel D Waksal said Chiromics technology and libraries indicates a paradigm shift in pharmaceutical drug discovery.
"This platform allows us to identify and produce high-value, pre-clinical candidates against virtually any biologic target with speed and specificity, a feat not possible with other chemistry libraries," Waksal added.
Related Insight
Suppliers Directory
DSM - Active Pharmaceutical Ingredients and Registered Intermediates
DSM is fully aligned with the needs of pharma and biotech, offering committed partnerships that apply our broad technologies, exceptional facilities, and regulatory excellence to the manufacture of customers’ products.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
FeF Chemicals - Manufacturer and Supplier of Benzalkonium Chloride
FeF Chemicals A/S manufactures and supplies Quaternary Ammonium Compounds (Quats), including Benzalkonium Chloride, for pharmaceutical and personal care products. FeF Chemicals also supplies Insulin for use in cell growth media. FeF Chemicals is a fully owned subsidiary of Novo Nordisk A/S, a Danish healthcare company and world leader in diabetes care.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
ISOCHEM - Fine Chemicals for the Pharmaceutical Industry
ISOCHEM, one of the leading suppliers of fine chemistry, is a 40 years old company with about 500 employees world wide. The Head office is located near Paris, in Vert-Le-Petit, France, on one of its five industrial sites.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Multipharma - Global Clinical Trial Supply and Comparator Drug Sourcing
Specialising in comparator drug sourcing activities while supporting the industry's global clinical supply chain.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Fine & Speciality Chemicals Intelligence
Catalyst Series
Published by Umicore Precious Metals Chemistry
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Highly Potent Active Pharmaceutical Ingredients
Published by Heraeus
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Optimising Excipient Properties for ODT Formulation
Published by Roquette Pharma
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.